Ignite Creation Date:
2024-05-06 @ 10:02 AM
Last Modification Date:
2024-10-26 @ 12:23 PM
Study NCT ID:
NCT03145311
Status:
COMPLETED
Last Update Posted:
2020-09-16
First Post:
2017-04-28
Brief Title:
First rTMS for Treatment of Drug Induced Tardive Syndromes Double Randomized Clinical Trial
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
First Repetitive Transcranial Magnetic Stimulation for Treatment of Drug Induced Tardive Syndromes Double Randomized Clinical Trial
Status:
COMPLETED
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to evaluate the efficacy of rTMS on DITS Twenty patients with DITS were recruited from the outpatient clinic of Aswan University Hospital The patients were classified into two equal groups 1st group received real high frequency rTMS at 100 RMT and the 2nd group received sham stimulation with the same pulse delivery but with the coil placed perpendicular to the scalp For each patient 10 sessions were administered once per day for 5 consecutive days each week for two weeks All patients were assessed before rTMS and immediately after the end of the 10 sessions This study is double blinded the doctor and the patients Assessment with AIMS scale and different parameters of cortical excitability were performed before and after the end of sessions treatment
Detailed Description:
The aim of this study was to evaluate the efficacy of repetitive transcranial magnetic stimulation rTMS on drug induced tardive syndromes
the effect of rTMS compare Twenty patients with drug induced tardive syndromes were recruited from the outpatient clinic of Aswan University Hospital The patients were classified into two equal groups 1st group received real 20 Hz-rTMS at 100 RMT a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s and the 2nd group received sham stimulation with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp For each patient 10 sessions were administered once per day for 5 consecutive days each week for two weeks All patients were assessed before rTMS and immediately after the end of the 10 sessions The patients did not know which type of stimulation they received and to ensure that the study was double blinded the doctor who assessed the patients didnt know which type of stimulation the patients received None of the patients had had rTMS before and were unaware of the type of stimulationThe AIMS scale and different parameters of cortical excitability were assessed before and after the end of session treatment
the effect of rTMS compare Twenty patients with drug induced tardive syndromes were recruited from the outpatient clinic of Aswan University Hospital The patients were classified into two equal groups 1st group received real 20 Hz-rTMS at 100 RMT a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s and the 2nd group received sham stimulation with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp For each patient 10 sessions were administered once per day for 5 consecutive days each week for two weeks All patients were assessed before rTMS and immediately after the end of the 10 sessions The patients did not know which type of stimulation they received and to ensure that the study was double blinded the doctor who assessed the patients didnt know which type of stimulation the patients received None of the patients had had rTMS before and were unaware of the type of stimulationThe AIMS scale and different parameters of cortical excitability were assessed before and after the end of session treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None